Clinical trial No longer in our active list Phase 2 Interventional Ages 18 to 90

Using nimodipine to protect nerves during vestibular schwannoma surgery

Official title: Intraoperative Application of Nimodipine to the Facial and Cochlear Nerves During Vestibular Schwannoma Resection to Avoid Spasm-related Postoperative Facial Paralysis and Deafness - a Prospective Randomized Pilot Study

Run by Medical University of Vienna · NCT04801953 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if using nimodipine during surgery for vestibular schwannomas can help protect the facial and hearing nerves to reduce the chances of paralysis and hearing loss afterward.

More Vestibular Schwannoma trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 90 Years
SexAll
Enrollment30 (estimated)
SponsorMedical University of Vienna
Academic / other
Locations1 site (Vienna)
Trial IDNCT04801953 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults over 18 years old with vestibular schwannomas measuring between 10 and 25 mm in diameter.

Probably not a fit

Patients with vestibular schwannomas smaller than 10 mm or larger than 25 mm, or those with contraindications for nimodipine, will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of nimodipine, a medication known for its neuroprotective properties, when applied directly to the facial and cochlear nerves during the surgical removal of vestibular schwannomas. It is a prospective, randomized, placebo-controlled, double-blinded trial aimed at determining whether nimodipine can reduce the risk of postoperative facial paralysis and hearing loss. Participants will be randomly assigned to receive either nimodipine or a placebo during their surgery, with outcomes assessed postoperatively.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the incidence of facial paralysis and deafness in patients undergoing vestibular schwannoma resection.

How similar studies have gone: Previous studies have suggested positive effects of nimodipine on nerve function preservation, indicating potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 18a
* Vestibular schwannoma with maximum diameter of 10-25mm on MRI
* Pre-operative audiogram
* Informed consent

Exclusion Criteria:

* Contraindication for nimodipine application
* Vestibularis schwannoma diameter \<10mm or \>25mm on MRI

Where it's running

  • Medical University of Vienna
    Vienna, Austria
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.